المؤلفون: Harrer, Dennis Christoph, Lüke, Florian, Pukrop, Tobias, Ghibelli, Lina, Gerner, Christopher, Reichle, Albrecht, Heudobler, Daniel

المساهمون: Harrer, Dc, Lüke, F, Pukrop, T, Ghibelli, L, Gerner, C, Reichle, A, Heudobler, D

مصطلحات موضوعية: all-trans retinoic acid, anakoinosis, dexamethasone, interferon-α, phenotypic plasticity, pioglitazone, transcriptional modulation, tumor tissue editing, Settore BIO/13

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/38273846; info:eu-repo/semantics/altIdentifier/wos/WOS:001149028800001; volume:13; numberofpages:16; journal:FRONTIERS IN ONCOLOGY; https://hdl.handle.net/2108/353508Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85182976686

الإتاحة: https://doi.org/10.3389/fonc.2023.1289222Test
https://hdl.handle.net/2108/353508Test

المؤلفون: Jiangang Zhang, Shaodan Peng, Fang Xu, Ying Qiao, Xiaoke Ye, Yu Guan, Xiaolong Zhao, Yueran Wang, Zhongqi Shao, Tao Zhu, Weixue Si

المصدر: Vaccine: X, Vol 17, Iss , Pp 100432- (2024)

مصطلحات موضوعية: Herpes zoster, Vaccine, Glycoprotein E, Interferon-α, Immunologic diseases. Allergy, RC581-607

العلاقة: http://www.sciencedirect.com/science/article/pii/S2590136224000056Test; https://doaj.org/toc/2590-1362Test; https://doaj.org/article/9ce3818211ab43b3a79bc874070bacbaTest

الإتاحة: https://doi.org/10.1016/j.jvacx.2024.100432Test
https://doaj.org/article/9ce3818211ab43b3a79bc874070bacbaTest

المؤلفون: Nan Geng, Lina Ma, Yi Jin, Junfeng Lu, Yanhong Zheng, Junli Wang, Xiaoxiao Wang, Xinyue Chen

المصدر: Diagnostics, Vol 14, Iss 1, p 118 (2024)

مصطلحات موضوعية: chronic hepatitis B, interferon-α, HbsAg clearance, prediction model, prospective case–control study, Medicine (General), R5-920

العلاقة: https://www.mdpi.com/2075-4418/14/1/118Test; https://doaj.org/toc/2075-4418Test; https://doaj.org/article/5d8fe75783d64e2e988cad14d70d651dTest

الإتاحة: https://doi.org/10.3390/diagnostics14010118Test
https://doaj.org/article/5d8fe75783d64e2e988cad14d70d651dTest

المؤلفون: Dennis Christoph Harrer, Florian Lüke, Tobias Pukrop, Lina Ghibelli, Christopher Gerner, Albrecht Reichle, Daniel Heudobler

المصدر: Frontiers in Oncology, Vol 13 (2024)

مصطلحات موضوعية: pioglitazone, interferon-α, dexamethasone, all-trans retinoic acid, tumor tissue editing, anakoinosis, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

العلاقة: https://www.frontiersin.org/articles/10.3389/fonc.2023.1289222/fullTest; https://doaj.org/toc/2234-943XTest; https://doaj.org/article/bf03ea496d9b4c92934b5b16e11cb96bTest

الإتاحة: https://doi.org/10.3389/fonc.2023.1289222Test
https://doaj.org/article/bf03ea496d9b4c92934b5b16e11cb96bTest

المؤلفون: Canbar, Rahmi, Dik, Irmak, Uslu, Muhittin, Ider, Merve, Arslan, Mustafa-Sedat, Yazar, Enver

المصدر: Revista Colombiana de Ciencias Pecuarias; Vol. 36 No. 4 (2023): October - December 2023; 210-215 ; Revista Colombiana de Ciencias Pecuarias; Vol. 36 Núm. 4 (2023): Octubre - Diciembre 2023; 210-215 ; Revista Colombiana de Ciencias Pecuarias; v. 36 n. 4 (2023): Outubro - Dezembro 2023; 210-215 ; 2256-2958

مصطلحات موضوعية: avermectins, immunity, immunoglobulin E, immunoglobulin G, immunoglobulin M, interferon-α, interleukin-2, interleukin-6, interleukin-10, ivermectin, sheep, tumor necrosis factor-α, avermectinas, factor de necrosis tumoral-α, inmunoglobulina E, inmunoglobulina G, inmunidad, inmunoglobulina M, interferón-α, interleucina-2, interleucina-6, interleucina-10, ivermectina, oveja, fator de necrose tumoral-α, imunoglobulina E, imunoglobulina G, imunoglobulina M, imunidade, interferão-α

وصف الملف: application/pdf

العلاقة: https://revistas.udea.edu.co/index.php/rccp/article/view/354287/20811802Test; https://revistas.udea.edu.co/index.php/rccp/article/view/354287Test

الإتاحة: https://revistas.udea.edu.co/index.php/rccp/article/view/354287Test

المؤلفون: García Ortega, María Belén, Aparicio, Ernesto, Griñán Lisón, Carmen, Jiménez González, Gema, López Ruiz, Elena, Palacios Ferrer, José Luis, Ruiz Alcalá, Gloria, Boulaiz Tassi, Houria, Perán, Macarena, Hackenberg, Michael, Marchal Corrales, Juan Antonio, García Chaves, María Ángel, Garcí

مصطلحات موضوعية: Interferon-α, Malignant melanoma, Cancer stem cells, Exosomes, Biomarkers

العلاقة: García-Ortega, M.B.; Aparicio, E.; Griñán-Lisón, C.; Jiménez, G.; López-Ruiz, E.; Palacios, J.L.; Ruiz-Alcalá, G.; Alba, C.; Martínez, A.; Boulaiz, H.; et al. Interferon-Alpha Decreases Cancer Stem Cell Properties and Modulates Exosomes in Malignant Melanoma. Cancers 2023, 15, 3666. [https:// doi.org/10.3390/cancers15143666]; https://hdl.handle.net/10481/84587Test

الإتاحة: https://doi.org/10.3390/cancers15143666Test
https://hdl.handle.net/10481/84587Test

المؤلفون: María Belén García-Ortega, Ernesto Aparicio, Carmen Griñán-Lisón, Gema Jiménez, Elena López-Ruiz, José Luis Palacios, Gloria Ruiz-Alcalá, Cristina Alba, Antonio Martínez, Houria Boulaiz, Macarena Perán, Michael Hackenberg, José Bragança, Sofia M. Calado, Juan A. Marchal, María Ángel García

المصدر: Cancers; Volume 15; Issue 14; Pages: 3666

مصطلحات موضوعية: interferon-α, malignant melanoma, cancer stem cells, exosomes, metabolomics, biomarkers

وصف الملف: application/pdf

العلاقة: https://dx.doi.org/10.3390/cancers15143666Test

الإتاحة: https://doi.org/10.3390/cancers15143666Test

المؤلفون: T. M. Reshetnyak, E. A. Aseeva, A. A. Shumilova, N. Yu. Nikishina, S. Yu. Shkireeva, A. M. Lila, Т. М. Решетняк, Е. А. Асеева, А. А. Шумилова, Н. Ю. Никишина, С. Ю. Шкиреева, А. М. Лила

المساهمون: The article was prepared within the framework of the basic scientific topic FURS-2022-003 №122040400024-07., Статья подготовлена в рамках фундаментальной темы FURS-2022-003 №122040400024-07.

المصدر: Modern Rheumatology Journal; Том 17, № 6 (2023); 14-21 ; Современная ревматология; Том 17, № 6 (2023); 14-21 ; 2310-158X ; 1996-7012

مصطلحات موضوعية: анифролумаб, interferon receptors, interferon α, anifrolumab, рецепторы интерферона, интерферон α

وصف الملف: application/pdf

العلاقة: https://mrj.ima-press.net/mrj/article/view/1497/1410Test; https://mrj.ima-press.net/mrj/article/view/1497/1412Test; Насонов ЕЛ, Соловьев СК, Аршинов АВ. Системная красная волчанка: история и современность. Научно-практическая ревматология. 2022;60(4):397-412.; Crow MK, Olferiev M, Kirou KA. Type I interferons in autoimmune disease. Annu Rev Pathol. 2019 Jan 24:14:369-393. doi:10.1146/annurev-pathol-020117-043952. Epub 2018 Oct 17.; Насонов ЕЛ, Авдеева АС. Иммуновоспалительные ревматические заболевания, связанные с интерфероном типа I: новые данные. Научно-практическая ревматология. 2019;57(4):452-461.; Rönnblom L, Leonard D. Interferon pathway in SLE: One key to unlocking the mystery of the disease. Lupus Sci Med. 2019 Aug 13;6(1):e000270. doi:10.1136/lupus-2018-000270. eCollection 2019.; Reshetnyak T, Nurbaeva K, Ptashnik I, et al. Markers of NETosis in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome. Int J Mol Sci. 2023; 24(11):9210. doi:10.3390/ijms24119210.; Sarkar MK, Hile GA, Tsoi LC, et al. Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa. Ann Rheum Dis. 2018 Nov; 77(11):1653-1664. doi:10.1136/annrheumdis-2018-213197. Epub 2018 Jul 18.; Braunstein I, Klein R, Okawa J, Werth VP. The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score. Br J Dermatol. 2012 May; 166(5):971-5. doi:10.1111/j.1365-2133.2012.10825.x.; Nzeusseu Toukap A, Galant C, Theate I, et al. Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus. Arthritis Rheum. 2007 May;56(5):1579-88. doi:10.1002/art.22578.; Castellano G, Cafiero C, Divella C, et al. Local synthesis of interferon-alpha in lupus nephritis is associated with type I interferons signature and LMP7 induction in renal tubular epithelial cells. Arthritis Res Ther. 2015 Mar 22;17(1):72. doi:10.1186/s13075-015-0588-3.; Shiozawa S, Kuroki Y, Kim M, et al. Interferonalpha in lupus psychosis. Arthritis Rheum. 1992 Apr;35(4):417-22. doi:10.1002/art.1780350410.; Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol. 2014:32: 513-45. doi:10.1146/annurev-immunol032713-120231. Epub 2014 Feb 6.; Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. 2014 Jan;14(1):36-49. doi:10.1038/nri3581.; Paredes JL, Niewold TB. Type I interferon antagonists in clinical development for lupus. Expert Opin Investig Drugs. 2020 Sep;29(9): 1025-1041. doi:10.1080/13543784.2020. 1797677. Epub 2020 Sep 1.; Chaichian Y, Strand V. Interferon-directed therapies for the treatment of systemic lupus erythematosus: a critical update. Clin Rheumatol. 2021 Aug;40(8):3027-3037. doi:10.1007/s10067-020-05526-1. Epub 2021 Jan 7.; Goulden B, Isenberg D. Anti-IFN R MAbs for the treatment of systemic lupus erythematosus. Expert Opin Biol Ther. 2021 Apr;21(4):519-528. doi:10.1080/14712598.2021.1841164. Epub 2020 Oct 30.; Peng L, Oganesyan V, Wu H, et al. Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibody. MAbs. 2015;7(2):428-39. doi:10.1080/19420862.2015.1007810.; Riggs JM, Hanna RN, Rajan B, et al. Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci Med. 2018 Apr 5;5(1): e000261. doi:10.1136/lupus-2018-000261. eCollection 2018.; Инструкция по медицинскому применению лекарственного препарата САФНЕЛО®, 300 мг (концентрат для приготовления раствора для инфузий). Регистрационное удостоверение ЛП-№(001857)-(РГ-RU) от 27.02.2023 г.; Petri M, Orbai AM, Alarcуn GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012 Aug;64(8): 2677-86. doi:10.1002/art.34473.; Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002 Feb;29(2): 288-91.; Albrecht J, Taylor L, Berlin JA, et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol. 2005 Nov;125(5):889-94. doi:10.1111/j.0022-202X.2005.23889.x.; Klein R, Moghadam-Kia S, LoMonico J, et al. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch Dermatol. 2011 Feb;147(2):203-8. doi:10.1001/archdermatol.2010.435; Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996 Mar;39(3): 363-9. doi:10.1002/art.1780390303.; McElhone K, Abbott J, Shelmerdine J, et al. Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis Rheum. 2007 Aug 15;57(6):972-9. doi:10.1002/art.22881; Yellen S. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACIT) measurement system. J Pain Symptom Manage. 1997 Feb;13(2):63-74. doi:10.1016/s0885-3924(96)00274-6.; Pilgaard T, Hagelund L, Stallknecht SE, et al. Severity of fatigue in people with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis – Results of a cross-sectional study. PLoS One. 2019 Jun 28;14(6):e0218831. doi:10.1371/journal.pone.0218831.; Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 Feb;4(2):295-306. doi:10.1111/j.1538-7836.2006.01753.x.; Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2017. 464 с.; Kalunian KC, Furie R, Morand EF, et al. A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus. Arthritis Rheumatol. 2023 Feb;75(2):253-265. doi:10.1002/art.42392. Epub 2022 Nov 11.; Morand EF, Trasieva T, Berglind A, et al. Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab. Ann Rheum Dis. 2018 May;77(5):706-713. doi:10.1136/annrheumdis-2017-212504. Epub 2018 Feb 2.; Асеева ЕА, Воробьева ЛД, Соловьев СК и др. Психометрические свойства русскоязычной версии специфического опросника LupusQol для оценки качества жизни, связанного со здоровьем, у пациентов с системной красной волчанкой. Научнопрактическая ревматология. 2018;56(2): 164-172.; Furie RA, Morand EF, Bruce IN, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019;(1):e208-19.; Morand EF, Furie R, Tanaka Y, et al; TULIP-2 Trial Investigators. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020 Jan 16;382(3):211-221. doi:10.1056/NEJMoa1912196. Epub 2019 Dec 18.; Bruce IN, Golam S, Steenkamp J, et al. Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus. J Comp Eff Res. 2022 Jul;11(10):765-777. doi:10.2217/cer-2022-0040. Epub 2022 May 12.; Neupane B, Shukla P, Slim M, et al. Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks. Lupus Sci Med. 2023 May;10(1):e000907. doi:10.1136/lupus-2023-000907.; https://mrj.ima-press.net/mrj/article/view/1497Test

الإتاحة: https://doi.org/10.14412/1996-7012-2023-6-14-21Test
https://doi.org/10.1146/annurev-pathol-020117-043952Test
https://doi.org/10.1136/lupus-2018-000270Test
https://doi.org/10.3390/ijms24119210Test
https://doi.org/10.1136/annrheumdis-2018-213197Test
https://doi.org/10.1111/j.1365-2133.2012.10825.xTest
https://doi.org/10.1002/art.22578Test
https://doi.org/10.1186/s13075-015-0588-3Test
https://doi.org/10.1002/art.1780350410Test
https://doi.org/10.1146/annurev-immunol032713-120231Test

المؤلفون: G. M. Ignatyev, E. Yu. Shustova, E. A. Rogozhina, P. A. Belyi, K. Ya. Zaslavskaya, V. A. Merkulov, Г. М. Игнатьев, Е. Ю. Шустова, Е. А. Рогожина, П. А. Белый, К. Я. Заславская, В. А. Меркулов

المساهمون: The study was performed without external funding

المصدر: Biological Products. Prevention, Diagnosis, Treatment; Том 23, № 3 (2023); 290-299 ; БИОпрепараты. Профилактика, диагностика, лечение; Том 23, № 3 (2023); 290-299 ; 2619-1156 ; 2221-996X

مصطلحات موضوعية: РАДАМИН®ВИРО, SARS-CoV-2, COVID-19, antiviral activity, interferon-α, interferon-γ, innate immunity, in vitro, Vero cells, RADAMIN®VIRO, противовирусная активность, интерферон α, интерферон γ, врожденный иммунитет, клеточная линия Vero

وصف الملف: application/pdf

العلاقة: https://www.biopreparations.ru/jour/article/view/453/742Test; https://www.biopreparations.ru/jour/article/downloadSuppFile/453/507Test; https://www.biopreparations.ru/jour/article/downloadSuppFile/453/750Test; Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91(1):157–60. https://doi.org/10.23750/abm.v91i1.9397Test; Seyedpour S, Khodaei B, Loghman AH, Seyedpour N, Kisomi MF, Balibegloo M, et al. Targeted therapy strategies against SARS‐CoV‐2, cell entry mechanisms: A systematic review of in vitro and in vivo studies. J Cell Physiol. 2020;236(4):2364–92. https://doi.org/10.1002/jcp.30032Test; Болевич CБ, Болевич СС. Комплексный механизм развития СOVID-19. Сеченовский вестник. 2020;11(2):50–61 https://doi.org/10.47093/2218-7332.2020.11.2.50-61Test; Andreev-Andrievskiy AA, Zinovkin RA, Mashkin MA, Frolova OY, Kazaishvili YG, Scherbakova VS, et al. Gene expression pattern of Peyer’s patch lymphocytes exposed to kagocel suggests pattern-recognition receptors mediate its action. Front Pharmacol. 2021;12:679511. https://doi.org/10.3389/fphar.2021.679511Test; Gu W, Gan H, Ma Y, Xu L, Cheng J, Li B, et al. The molecular mechanism of SARS-CoV-2 evading host antiviral innate immunity. Virol J. 2022;19(1):49. https://doi.org/10.1186/s12985-022-01783-5Test; Костинов МП, Маркелова ЕВ, Свитич ОА, Полищук ВБ. Иммунные механизмы SARS-СoV-2 и потенциальные препараты для профилактики и лечения COVID-19. Пульмонология. 2020;30(5):700–8. https://doi.org/10.18093/0869-0189-2020-30-5-700-708Test; Barnard DL, Day CW, Bailey K, Heiner M, Montgomery R, Lauridsen L, et al. Evaluation of immunomodulators, interferons and known in vitro SARS-CoV inhibitors for inhibition of SARS-CoV replication in BALB/c mice. Antivir Chem Chemother. 2006;17(5):275–84. https://doi.org/10.1177/095632020601700505Test; Day CW, Baric R, Cai SX, Frieman M, Kumaki Y, Morrey JD, et al. A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo. Virology. 2009;395(2):210–22. https://doi.org/10.1016/j.virol.2009.09.023Test; Overton ET, Goepfert PA, Cunningham P, Carter WA, Horvath J, Young D, Strayer DR. Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans. Vaccine. 2014;32(42):5490–5. https://doi.org/10.1016/j.vaccine.2014.07.078Test; Kozlowski A, Charles SA, Harris JM. Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs. 2001;15(7):419–29. https://doi.org/10.2165/00063030-200115070-00001Test; Nicodemus CF, Berek JS. TLR3 agonists as immunotherapeutic agents. Immunotherapy. 2010;2(2):137–40. https://doi.org/10.2217/imt.10.8Test; Mustafa DAM, Saida L, Latifi D, Wismans LV, de Koning W, Zeneyedpour L. Rintatolimod induces antiviral activities in human pancreatic cancer cells: opening for an Anti-COVID-19 opportunity in cancer patients. Cancers (Basel). 2021;13(2):2896. https://doi.org/10.3390/cancers13122896Test; Ершов ФИ, Киселев ОИ. Интерфероны и их индукторы (от молекул до лекарств). М.: ГЭОТАР-Медиа; 2005.; Kozlovskaya L, Piniaeva A, Ignatyev G, Selivanov A, Shishova A, Kovpak A, et al. Isolation and phylogenetic analysis of SARS-CoV-2 variants collected in Russia during the COVID-19 outbreak. Int J Infect Dis. 2020;99:40–6. https://doi.org/10.1016/j.ijid.2020.07.024Test; Ianevski A, Yao R, Zusinaite E, Lello LS, Wang S, Jo E, et al. Synergistic interferon-alpha-based combinations for treatment of SARS-CoV-2 and other viral infections. Viruses. 2021;13(12):2489. https://doi.org/10.3390/v13122489Test; Sallard E, Lescure FX, Yazdanpanah Y, Mentre F, Peiffer-Smadja N. Type 1 interferons as a potential treatment against COVID-19. Antiviral Res. 2020;178:104791. https://doi.org/10.1016/j.antiviral.2020.104791Test; Ribero MS, Jouvenet N, Dreux M, Nisole S. Interplay between SARS-CoV-2 and the type I interferon response. PLoS Pathog. 2020;16(7):e1008737. https://doi.org/10.1371/journal.ppat.1008737Test; Todorović-Raković N, Whitfield JR. Between immunomodulation and immunotolerance: The role of IFNγ in SARS-CoV-2 disease. Cytokine. 2021;146:155637. https://doi.org/10.1016/j.cyto.2021.155637Test; Karber G. Beitragzurkollecktiven behandlungpharmakologischer reihenversuche. Arch Exptl Pathol Pharmakol. 1931;162:480–3.; Villinger F, Brar SS, Mayne A, Chikkala N, Ansari AA. Comparative sequence analysis of cytokine genes from human and nonhuman primates. J Immunol. 1995;155:3946–54. https://doi.org/10.4049/jimmunol.155.8.3946Test; Felger JS, Alagbe O, Hu F, Mook D, Freeman AA, Sanchez MM, et al. Effects of interferon-alpha on rhesus monkeys: a non-human primate model of cytokine-induced depression. Biol Psychiatry. 2007;62(11):1324–33. https://doi.org/10.1016%2Fj.biopsych.2007.05.026Test; Willette AA, Lubach GR, Coe CL. Environmental context differentially affects behavioral, leukocyte, cortisol, and interleukin-6 responses to low doses of endotoxin in the rhesus monkey. Brain Behav Immun. 2007;21(6):807–15. https://doi.org/10.1016/j.bbi.2007.01.007Test; https://www.biopreparations.ru/jour/article/view/453Test

الإتاحة: https://doi.org/10.30895/2221-996X-2023-23-3-290-299Test
https://doi.org/10.23750/abm.v91i1.9397Test
https://doi.org/10.1002/jcp.30032Test
https://doi.org/10.47093/2218-7332.2020.11.2.50-61Test
https://doi.org/10.3389/fphar.2021.679511Test
https://doi.org/10.1186/s12985-022-01783-5Test
https://doi.org/10.18093/0869-0189-2020-30-5-700-708Test
https://doi.org/10.1177/095632020601700505Test
https://doi.org/10.1016/j.virol.2009.09.023Test
https://doi.org/10.1016/j.vaccine.2014.07.078Test

المؤلفون: Suresh Sharma, Paresh Kumar Sarma, Uddip Talukdar, Ramen Talukdar, Nalini Mishra, Dipankar Baruah, Rizwana Sultana, Abhijit Bharali

المصدر: Indian Journal of Allergy Asthma and Immunology, Vol 37, Iss 1, Pp 21-29 (2023)

مصطلحات موضوعية: clinical outcome, covid-19, cytokines, disease severity, interferon-α, interleukin-17a, interleukin-6, Immunologic diseases. Allergy, RC581-607

العلاقة: http://www.ijaai.in/article.asp?issn=0972-6691;year=2023;volume=37;issue=1;spage=21;epage=29;aulast=SharmaTest; https://doaj.org/toc/0972-6691Test; https://doaj.org/article/cebf88f3e1454c658278d27eb472012cTest

الإتاحة: https://doi.org/10.4103/ijaai.ijaai_19_23Test
https://doaj.org/article/cebf88f3e1454c658278d27eb472012cTest